Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 02 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone; Rituximab; Vincristine
Indications B-cell lymphoma
Focus Adverse reactions; Therapeutic Use

26 Apr 2023 Planned primary completion date changed from 29 Jul 2022 to 29 Jul 2023.
13 Dec 2022 Primary endpoint (2-year Progression free survival (Phase II)) has been met, as per results presented at the 64th American Society of Hematology Annual Meeting and Exposition.
13 Dec 2022 Primary endpoint (1 year Progression free survival (Phase II)) has been met, as per results presented at the 64th American Society of Hematology Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com